Dexcom reported Q1 revenue of $1.19 billion, up 15% YoY, surpassing the $1.18 billion consensus estimate.
Adjusted earnings were 56 cents per share, beating analysts’ expectation of 47 cents, while the stock fell 4.3% after hours.
Dexcom reaffirmed its FY2026 revenue outlook of $5.16‑$5.25 billion, roughly in line with analysts’ $5.23 billion forecast.
The company expanded U.S. launch of its G7 15‑day sensor, added meal‑logging to Stelo, and released data on type‑2 diabetes benefits.